PT2120568T - Rácios de fármacos fixados para tratamento de cancros hematopoiéticos e desordens proliferativas - Google Patents

Rácios de fármacos fixados para tratamento de cancros hematopoiéticos e desordens proliferativas

Info

Publication number
PT2120568T
PT2120568T PT87300489T PT08730048T PT2120568T PT 2120568 T PT2120568 T PT 2120568T PT 87300489 T PT87300489 T PT 87300489T PT 08730048 T PT08730048 T PT 08730048T PT 2120568 T PT2120568 T PT 2120568T
Authority
PT
Portugal
Prior art keywords
treatment
proliferative disorders
hematopoietic cancers
fixed drug
drug ratios
Prior art date
Application number
PT87300489T
Other languages
English (en)
Portuguese (pt)
Inventor
Louie Arthur
Swenson Christine
Mayer Lawrence
Janoff Andrew
Original Assignee
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2120568(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celator Pharmaceuticals Inc filed Critical Celator Pharmaceuticals Inc
Publication of PT2120568T publication Critical patent/PT2120568T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
PT87300489T 2007-02-16 2008-02-15 Rácios de fármacos fixados para tratamento de cancros hematopoiéticos e desordens proliferativas PT2120568T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90177207P 2007-02-16 2007-02-16
US96519607P 2007-08-17 2007-08-17

Publications (1)

Publication Number Publication Date
PT2120568T true PT2120568T (pt) 2017-12-04

Family

ID=39690832

Family Applications (2)

Application Number Title Priority Date Filing Date
PT87300489T PT2120568T (pt) 2007-02-16 2008-02-15 Rácios de fármacos fixados para tratamento de cancros hematopoiéticos e desordens proliferativas
PT172004988T PT3300601T (pt) 2007-02-16 2008-02-15 Proporções fixas de medicamentos para o tratamento do cânceres hematopoiéticos e distúrbios proliferativos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT172004988T PT3300601T (pt) 2007-02-16 2008-02-15 Proporções fixas de medicamentos para o tratamento do cânceres hematopoiéticos e distúrbios proliferativos

Country Status (20)

Country Link
US (2) US8092828B2 (enExample)
EP (3) EP2120568B1 (enExample)
JP (1) JP5314600B2 (enExample)
KR (2) KR20100014441A (enExample)
CN (1) CN105998046A (enExample)
AU (1) AU2008216083B2 (enExample)
CA (1) CA2678332C (enExample)
CY (1) CY1119631T1 (enExample)
DK (2) DK3300601T3 (enExample)
ES (2) ES2650167T3 (enExample)
FR (1) FR22C1034I2 (enExample)
HR (1) HRP20220428T3 (enExample)
HU (2) HUE058334T2 (enExample)
LU (1) LUC00271I2 (enExample)
NL (1) NL301185I2 (enExample)
NO (2) NO2120568T3 (enExample)
PL (2) PL3300601T3 (enExample)
PT (2) PT2120568T (enExample)
SI (1) SI3300601T1 (enExample)
WO (1) WO2008101214A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036822A1 (en) * 2008-09-24 2010-04-01 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
JP6133308B2 (ja) 2011-10-21 2017-05-24 セレーター ファーマシューティカルズ インコーポレイテッド 凍結乾燥リポソーム
US20140154304A1 (en) * 2012-11-30 2014-06-05 Boehringer Ingelheim International Gmbh Combination therapy with volasertib
WO2015127173A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015127172A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
BR112018009463A8 (pt) 2015-11-11 2019-02-26 Celator Pharmaceuticals Inc ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2019023873A1 (zh) * 2017-07-31 2019-02-07 江苏竞诺择生物医药科技有限公司 一种用于治疗造血系统增殖性疾病的纳米脂质微粒组合物及药用组合物
US20240252522A1 (en) 2018-09-25 2024-08-01 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders
CA3121902A1 (en) 2018-12-04 2020-06-11 Der-Yang Tien Stereocomplexes for the delivery of anti-cancer agents
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
US11980636B2 (en) * 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
WO2025088367A1 (en) * 2023-10-27 2025-05-01 Jodas Expoim Pvt. Ltd Liposomal composition of idarubicin and cytarabine and process for preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
CA2505003A1 (en) * 2002-11-06 2004-05-27 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
BR0215935A (pt) * 2002-11-06 2005-08-09 Wyeth Corp Terapia combinada para tratamento de leucemia aguda e sìndrome mielodisplásica
CA2564542C (en) * 2004-04-22 2012-11-27 Celator Pharmaceuticals, Inc. Combination formulations of anthracycline agents and cytidine analogs
SE0402025D0 (sv) * 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
EP1976485A4 (en) 2005-12-22 2011-10-26 Celator Pharmaceuticals Inc LIPOSOMAL FORMULATIONS WITH SECONDARY AND TERTIARY AMINES AND METHOD OF MANUFACTURING THEREOF

Also Published As

Publication number Publication date
KR20100014441A (ko) 2010-02-10
EP2120568A2 (en) 2009-11-25
DK2120568T3 (en) 2017-12-11
ES2909903T3 (es) 2022-05-10
EP3300601A1 (en) 2018-04-04
PL3300601T3 (pl) 2022-05-02
US8092828B2 (en) 2012-01-10
CA2678332C (en) 2015-06-02
ES2650167T3 (es) 2018-01-17
PT3300601T (pt) 2022-04-21
FR22C1034I2 (fr) 2023-06-30
EP3300601B1 (en) 2022-01-12
LUC00271I2 (enExample) 2025-04-25
AU2008216083B2 (en) 2014-02-06
EP4046640A1 (en) 2022-08-24
CA2678332A1 (en) 2008-08-21
SI3300601T1 (sl) 2022-05-31
CY1119631T1 (el) 2018-04-04
DK3300601T3 (da) 2022-03-21
CN105998046A (zh) 2016-10-12
AU2008216083A2 (en) 2009-09-24
NL301185I2 (nl) 2022-07-21
NO2120568T3 (enExample) 2018-04-14
FR22C1034I1 (fr) 2022-09-09
WO2008101214A2 (en) 2008-08-21
EP2120568A4 (en) 2010-04-21
KR20150038752A (ko) 2015-04-08
HUE058334T2 (hu) 2022-07-28
AU2008216083A1 (en) 2008-08-21
WO2008101214A3 (en) 2008-11-20
NO2022027I1 (no) 2022-06-30
HUS2200032I1 (hu) 2022-07-28
HK1253378A1 (en) 2019-06-14
PL2120568T3 (pl) 2018-03-30
US20080199515A1 (en) 2008-08-21
EP2120568B1 (en) 2017-11-15
JP5314600B2 (ja) 2013-10-16
US20100303895A1 (en) 2010-12-02
HRP20220428T3 (hr) 2022-05-27
JP2010519224A (ja) 2010-06-03

Similar Documents

Publication Publication Date Title
HUS2200032I1 (hu) Rögzített gyógyszerarányok hematopoietikus rákok és proliferatív rendellenességek kezelésére
IL249102A0 (en) Melatonin tablet and methods for preparation and use
IL198596A0 (en) Thienopyrimidinones for treatment of inflammatory disorders and cancers
PL2322221T3 (pl) Kompozycja farmaceutyczna do leczenia i zapobiegania raka
ZA201300692B (en) Administration of hypoxia activated prodrugs and antiagiogenic agents for the treatment of cancer
GB2454118B (en) Hdac inhibitors and hormone targeted drugs for the treatment of cancer
EP2211854A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS
PT2340042E (pt) Métodos e composições para o tratamento de cancro
EP2205236A4 (en) NEW MEANS FOR THE TREATMENT OF DISEASES AND FUNCTIONAL DISORDERS
IL207046A (en) Quinazoline derivatives for the treatment of cancer-related disorders
AP3480A (en) Phosphaplatins and their use for treatment of cancers
IL214349A0 (en) Compositions and methods for the treatment of cancer
IL202307A (en) Multikinase inhibitors for use in the preparation of pharmaceuticals for the treatment of various cancers
PL2305300T3 (pl) Kompozycja farmaceutyczna do leczenia i zapobiegania nowotworowi
EP2377934A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMOR AND ASTHMA
PL2331092T3 (pl) Sposoby i kompozycje do podawania 3-halopirogronianiu i związków pochodnych w leczeniu nowotworu
IL200966A0 (en) Tetrahydroquinoline derivatives and the use thereof for the treatment of cancer
IL205339A0 (en) Compounds and methods for the treatment of cancer
HK1170238A (en) Indolyl-substituted pyrazino-quinolines and their use for the treatment of cancer
GB0700281D0 (en) Methods and Means for the Treatment of Cancer
GB0722706D0 (en) Cancer treatment medicament use and method of manufacture thereof
AU2010901813A0 (en) Avian-Based Treatment For Proliferative Skin Disorders and Cancers
HK1135980A (en) Thienopyrimidinones for treatment of inflammatory disorders and cancers
IL201502A0 (en) Methods and compositions for contributing to the treatment of cancers
GB0622471D0 (en) Use of reversine and analogs for treatment of cancer